CariPHLN Bulletin - CARPHA
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CariPHLN No. 10
March 8, 2021
Bulletin
Current News from the
Caribbean Public Health
Laboratory Network
INSIDE THIS ISSUE COVID-19 Vaccines
1. COVID-19 Vaccines In light of the current health crisis, much sad news has been
2. Biosafety and Biosecurity reported. However, there has been news that brings us some
3. Climate Change and Health hope that the crisis will have an end.
Leadership Fellowship
4. CARPHA 65th Annual Health
One of these is the development of COVID-19 vaccines.
Research Conference
Globally, there are many vaccines in development and some
5. Announcement: World Microbe
of these have been given WHO emergency use authorization,
Forum
while others have received country use authorizations. In
6. Resources UPDATE this issue we will focus some of our attention on some of
these vaccines. At present, there are over 90 vaccine
candidates, 11 of which have received approval by at least 1
country.
To date, in the US over 45 million vaccine doses have been
administered. For a country such as Canada, as at January,
about 2% of the population has already received their first
dose. In the UK, some 13 million people have received this
first dose, while in the EU, over 18 million vaccine doses
have already been administered.
Visit the CARPHA website for more on COVID-19 in the Caribbean
https://carpha.org/What-We-Do/Public-Health/Novel-Coronavirus
CariPHLN
Bulletin Page 2
The Caribbean Public Health Agency recognizes vaccines approved by the World Health Organization for
its Emergency Use Listing (EUL), and those approved by trusted regulatory authorities: US Food and Drug
Administration, Health Canada, Medicines and Healthcare Products Regulatory Agency (MHRA, UK),
Therapeutic Goods Administration (Australia), Swissmedic (Switzerland) and the European Union. Eligible
vaccines may be verified via the Caribbean Regulatory System (CRS) through dossier review, to ensure
that the manufacturer proposes the same vaccine of proven quality, safety and efficacy to CARPHA
Member States as what was approved. To date, there are six vaccines that are eligible for review by the
CRS - Table 1. The COVISHIELD™ vaccine by Serum Institute of India has been reviewed and
recommended by the CRS to Member States.
Table 1: COVID-19 Vaccines with Recognized Approvals – 7th March, 2021
Vaccine name Manufacturer Vaccine Type Efficacy¥ Approved by WHO EUL status and
anticipated decision
date:
Tozinameran (INN); Pzifer + BioNTech mRNA 95% WHO EUL + 68 countries December 2020
BNT162b2 / including United Kingdom, (completed)
COMIRNATY™ Canada, USA, Chile, Argentina,
Switzerland, European Union
ChAdOx1-S (AZD1222) AstraZeneca + Recombinant 63.1% 68 countries including UK, In progress: March-
Oxford University ChAdOx1 Argentina, Mexico, Brazil, EU, April
adenoviral vector Canada
ChAdOx1-S (AZD1222) AstraZeneca + Recombinant 63.1% WHO EUL + South Korea Approved: 15th
Oxford + SK ChAdOx1 For COVAX (Americas via PAHO) February
Biosciences adenoviral vector
ChAdOx1-S (AZD1222); Serum Institute of Recombinant 63.1% WHO EUL + 17 countries Approved: 15th
COVISHIELD™ India + ChAdOx1 including India, Argentina, South February
AstraZeneca & adenoviral vector Africa, Guyana, Canada (+Verity
Oxford University Pharma); CRS
mRNA-1273 Moderna & NIAID mNRA-based 94.5% 40 countries including Canada, In progress – March
vaccine Switzerland, United Kingdom,
encapsulated in United States, EU, Guyana
lipid nanoparticle
(LNP)
JNJ-78436735 Janssen Recombinant, 85% 4 countries: USA, Canada, South In progress – March
(Ad26.COV2.S) Pharmaceutical adenovirus type 26 Africa, Bahrain (3-5 days after EMA)
(Johnson & (Ad26) vectored
Johnson) vaccine
Key:
EUL – emergency use listing
NIAID – National Institute for Allergy and Infectious Diseases
¥ - Efficacy in the prevention of severe COVID-19 disease based on standard doses given during Phase 3
studies.
CariPHLN Bulletin No.10: March 8, 2021
CariPHLN
Bulletin Page 3
Canadian National COVID Genomics
Surveillance Priorities for Existing
BIOSAFETY AND BIOSECURITY UPDATE and Emerging Variants of Concern
3rd Annual Global Biosecurity Dialogue
The document describes the priorities for
NTI bio brought global biosecurity leaders together surveillance of SARS-CoV-2 virus in circulation,
with more than 140 participants registered from 36 existing variants of concern and those emerging.
different countries across six continents. The
meeting occurred over five sessions from 9 – 23rd Click here for the link to the document.
February, 2021 and sought to “enable new actions
to fix biosecurity gaps exposed or exacerbated by
the COVID-19 pandemic; encourage participants to
take on new or build upon existing efforts that
mitigate emerging risks such as those posed by
advances in biotechnology; and secure and
maintain political and financial support for
sustainable global biosecurity efforts through
collaboration with fora like the GHSA and Global
Partnership”.
Climate Change and Health
Leadership Fellowship
Call for Applications for UWI CARIFORUM Climate
Change and Health Leaders Fellowship Programme
- PAHO/WHO. Click here
The Caribbean Public Health Agency (CARPHA) in Announcement!
its role as Chair of the GHSA APP3 delivered two
separate presentations during the opening plenary
session on the 9th February 2021.
Executive Director, Dr. Joy St. John spoke on
behalf of the 60 plus APP3 membership as part of a
panel to discuss “Global and Regional Biosecurity
Initiatives: Progress, Challenges, and
Trajectories”. Ms. Sacha Wallace-Sankarsingh,
Biorisk Manager and Chair, GHSA APP3 then
presented an Analysis of Actions Taken to Advance
Global Biosecurity Targets in 2020. The
presentation included findings from a framing
paper which served as a guide for the Dialogue’s
three workstream sessions including challenges
and opportunities presented during the COVID-19
pandemic.
CariPHLN Bulletin No.10: March 8, 2021
CariPHLN
Bulletin Page 4
Announcements! COVID-19 Resources
st
• ABSA International 1 Biosecurity Virtual
Symposium, April 21-22, 2021 Laboratory testing:
Link: https://biosecuritysymposium.org/
Caribbean Public Health Agency (CARPHA)
Pan American Health Organization (PAHO)
United States Centers for Disease Control
(CDC)
Foundation for Innovative New Diagnostics
(FINDD)
World Health Organization (WHO)
World Microbe Forum 20-24 June 2021:
collaboration between the American Society for
Microbiology (ASM) and the Federation of Laboratory Biosafety and Biosecurity
European Microbiological Societies (FEMS). guidelines:
Click here for more information.
o Jan. 11, 2021: Abstract Submission and
Awards/Grants Open
United States Centers for Disease Control
o Mar. 18, 2021: Abstract Submission and (CDC)
Awards/Grants Close Canada/Public Health Canada (PHAC)
o Mid-March 2021: Registration Opens International Federation of Biosafety
Associations (IFBA)
World Health Organization (WHO)
UPDATED
Laboratory biosafety guidance related to
coronavirus disease (COVID-19): Interim
guidance, 28 January 2021:
Special COVID-19 LabCoP ECHO Session #37 https://www.who.int/publications/i/item
on 2 March /WHO-WPE-GIH-2021.1
Click here for meeting link
Version 2 of the COVID-19 Antigen Rapid
Diagnostic Training Package
Click here
CariPHLN Secretariat For more information on CariPHLN Contact
The Caribbean Public Health Agency
16-18 Jamaica Boulevard Lisa Sandy
Federation Park, Port of Spain CariPHLN Manager
Trinidad and Tobago sandylis@carpha.org
© CARPHA 2020
postmaster@carpha.org
CariPHLN Bulletin No.10: March 8, 2021You can also read
